Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1281746 | 1.00 | TSHR (0.36) | TSHRCYP2D6CYP2C19HIF1AKDM4E | |
| SCHEMBL1282328 | 0.78 | KMT2A (0.31) | ALDH1A1 | |
| SCHEMBL1282326 | 0.78 | KMT2A (0.31) | ALDH1A1 | |
| SCHEMBL10789922 | 0.76 | KDM4E (0.39) | TSHRCYP2D6CYP2C19HIF1AKDM4E | |
| SCHEMBL10768836 | 0.73 | TSHR (0.36) | TSHRCYP2D6CYP2C19HIF1AHMGCR | |
| SCHEMBL3457363 | 0.73 | TSHR (0.36) | TSHRCYP2D6CYP2C19HIF1AHMGCR | |
| SCHEMBL4669160 | 0.73 | KDM4E (0.31) | CYP2C19KDM4EHMGCRCHRM1TBXA2R | |
| SCHEMBL1281592 | 0.73 | TSHR (0.36) | TSHRCYP2D6CYP2C19HIF1AHMGCR | |
| SCHEMBL1281593 | 0.73 | TSHR (0.36) | TSHRCYP2D6CYP2C19HIF1AHMGCR | |
| SCHEMBL27466000 | 0.73 | GGT1 (0.33) | TSHRCYP2D6CYP2C19HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9005920-B2 | Solution for cell-free protein synthesis, kit for cell-free protein synthesis, and method of protein synthesis | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2447365-A1 | CELL-FREE PROTEIN SYNTHESIS SOLUTION, CELL-FREE PROTEIN SYNTHESIS KIT, AND PROTEIN SYNTHESIS METHOD | Toyota Jidosha Kabushiki Kaisha (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20120088269-A1 | SOLUTION FOR CELL-FREE PROTEIN SYNTHESIS, KIT FOR CELL-FREE PROTEIN SYNTHESIS, AND METHOD OF PROTEIN SYNTHESIS | TOYOTA JIDOSHA KABUSHIKI KAISHA (JP) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088269-A1 | SOLUTION FOR CELL-FREE PROTEIN SYNTHESIS, KIT FOR CELL-FREE PROTEIN SYNTHESIS, AND METHOD OF PROTEIN SYNTHESIS | SMS, RNMT, SET | TSHR 4454/4885CYP2D6 3915/4885CYP2C19 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.